Abstract
Regulatory elements of the osteopontin (opn) gene are attractive candidates for expressiontargeted gene therapy because numerous malignant cancers are marked by opn overexpression. The maximum opn promoter (Popn)-driven reporter intensity obtained for tested cancer cell lines was as strong (102.69%) as positive-control transfections. At the same time, Popn-driven reporter expression was reduced by ~90% in non-cancer cell lineages. Deletion analysis of the -922 bp region opn promoter did not confirm published reports of a repressor area within 922 bases upstream of the transcriptional start site. Further enhancements to targeting and expression were obtained through incorporation of single-nucleotide polymorphisms (SNPs) into the promoter sequence. It was found that the SNPs -443C, -155GG, -66T led to increased Popn-driven transfection in cancer cells (fold increase of 1.23 ~ 3.48), with a concomitant decrease in reporter expression in normal controls (fold change of 0.69). Further investigations to confirm a correlation between endogenous opn mRNA levels and Popn-driven reporter expression produced a surprising lack of correlation (R2=0.24). However, taking into account opn mRNA splicing variants showed a strong negative correlation between mRNA levels of the variant opn-a and P opn-driven transgene activity (R2=0.95). These data have implications on how future searches for expression-targeting promoters should be conducted.
Keywords: Alternative splicing, expression-targeting, gene delivery, SNP, SPP1.
Current Gene Therapy
Title:The Potential of the Human Osteopontin Promoter and Single-Nucleotide Polymorphisms for Targeted Cancer Gene Therapy
Volume: 15 Issue: 1
Author(s): X.G. Chen and W.T. Godbey
Affiliation:
Keywords: Alternative splicing, expression-targeting, gene delivery, SNP, SPP1.
Abstract: Regulatory elements of the osteopontin (opn) gene are attractive candidates for expressiontargeted gene therapy because numerous malignant cancers are marked by opn overexpression. The maximum opn promoter (Popn)-driven reporter intensity obtained for tested cancer cell lines was as strong (102.69%) as positive-control transfections. At the same time, Popn-driven reporter expression was reduced by ~90% in non-cancer cell lineages. Deletion analysis of the -922 bp region opn promoter did not confirm published reports of a repressor area within 922 bases upstream of the transcriptional start site. Further enhancements to targeting and expression were obtained through incorporation of single-nucleotide polymorphisms (SNPs) into the promoter sequence. It was found that the SNPs -443C, -155GG, -66T led to increased Popn-driven transfection in cancer cells (fold increase of 1.23 ~ 3.48), with a concomitant decrease in reporter expression in normal controls (fold change of 0.69). Further investigations to confirm a correlation between endogenous opn mRNA levels and Popn-driven reporter expression produced a surprising lack of correlation (R2=0.24). However, taking into account opn mRNA splicing variants showed a strong negative correlation between mRNA levels of the variant opn-a and P opn-driven transgene activity (R2=0.95). These data have implications on how future searches for expression-targeting promoters should be conducted.
Export Options
About this article
Cite this article as:
Chen X.G. and Godbey W.T., The Potential of the Human Osteopontin Promoter and Single-Nucleotide Polymorphisms for Targeted Cancer Gene Therapy, Current Gene Therapy 2015; 15 (1) . https://dx.doi.org/10.2174/1566523214666141127094033
DOI https://dx.doi.org/10.2174/1566523214666141127094033 |
Print ISSN 1566-5232 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5631 |
Call for Papers in Thematic Issues
Programmed Cell Death Genes in Oncology: Pioneering Therapeutic and Diagnostic Frontiers (BMS-CGT-2024-HT-45)
Programmed Cell Death (PCD) is recognized as a pivotal biological mechanism with far-reaching effects in the realm of cancer therapy. This complex process encompasses a variety of cell death modalities, including apoptosis, autophagic cell death, pyroptosis, and ferroptosis, each of which contributes to the intricate landscape of cancer development and ...read more
Related Journals
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Astaxanthin Combine with Human Serum Albumin to Abrogate Cell Proliferation, Migration, and Drug-resistant in Human Ovarian Carcinoma SKOV3 Cells
Anti-Cancer Agents in Medicinal Chemistry Cardiac Multidetector Computed Tomography: Basic Physics of Image Acquisition and Clinical Applications
Current Cardiology Reviews Specific Synthesis of 1,5-Disubstituted-1,2,3-triazolines Catalyzed by Surface Modified Activated Carbon with MsOH
Current Organic Synthesis PPARγ: Potential Therapeutic Target for Ailments Beyond Diabetes and its Natural Agonism
Current Drug Targets Promoting Well-being and Resilience in Employing a Relationship Centered Approach: A Case Study of a Pre-adolescent Boy
Adolescent Psychiatry Diagnostic Usefulness of Tumor Markers in the Thyroid Cytological Samples Extracted by Fine-Needle Aspiration Biopsy
Endocrine, Metabolic & Immune Disorders - Drug Targets Status of Non-Classical Mononuclear Platinum Anticancer Drug Development
Mini-Reviews in Medicinal Chemistry Disintegrins
Current Drug Targets - Cardiovascular & Hematological Disorders Radiosynthesis of N.C.A. Sodium [18F]Fluoroacetate and Radiopharmacological Characterization in Rats and Tumor-Xenografted Mice
Current Radiopharmaceuticals [General Articles] Recent Developments in the Synthesis and Discovery of Oligosaccharides and Glycoconjugates for the Treatment of Disease
Current Medicinal Chemistry Therapeutic Options in Prevention and Treatment of Aspartoacylase Gene Mutation Resulting Abnormalities in Canavan Disease
Current Pharmacogenomics Stem Cells in Adult Human Ovaries: From Female Fertility to Ovarian Cancer
Current Pharmaceutical Design Dietary Phenolic Acids and Flavonoids as Potential Anti-Cancer Agents: Current State of the Art and Future Perspectives
Anti-Cancer Agents in Medicinal Chemistry Tyrosine Kinase Receptors Signaling Revealed by Global Expression Profiles: Implications for Cancer Biology
Current Genomics Trypanocidal Activity of Nitroaromatic Prodrugs: Current Treatments and Future Perspectives
Current Topics in Medicinal Chemistry Diagnosis and New Treatment Modalities for Glioblastoma: Do They Improve Patient Survival?
Current Molecular Medicine Target Acquired: Progress and Promise of Targeted Therapeutics in the Treatment of Prostate Cancer
Current Cancer Drug Targets The Role of Bone Density Measurements in the Evaluation of New Treatments for Osteoporosis
Current Pharmaceutical Design Estrogen Receptor Polymorphisms: Significance to Human Physiology, Disease and Therapy
Recent Patents on DNA & Gene Sequences DNA Repair in Premature Aging Disorders and Neurodegeneration
Current Aging Science